医学
美罗华
临时的
有效扩散系数
核医学
淋巴瘤
磁共振成像
中期分析
进行性疾病
临床试验
放射科
内科学
化疗
历史
考古
作者
Marius E. Mayerhoefer,Georgios Karanikas,Kurt Kletter,Barbara Kiesewetter,Michael A. Weber,Ivo Rausch,Matthias Pones,Ingrid Simonitsch-Klupp,Leonhard Müllauer,Werner Dolak,Julius Lukas,Markus Raderer
出处
期刊:Clinical Nuclear Medicine
[Ovid Technologies (Wolters Kluwer)]
日期:2016-11-01
卷期号:41 (11): 837-843
被引量:18
标识
DOI:10.1097/rlu.0000000000001395
摘要
Purpose To determine whether interim 18F-FDG PET or interim diffusion-weighted magnetic resonance imaging (DWI) can predict the end-of-treatment (EOT) outcome after immunotherapy in patients with FDG-avid extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT). Materials and Methods Patients with untreated MALT lymphoma prospectively underwent whole-body 18F-FDG PET/CT and DWI before treatment (baseline), and after three cycles (interim) of rituximab-based immunotherapy. Maximum and mean standardized uptake values (SUVmax, SUVmean), and minimum and mean apparent diffusion coefficients (ADCmin, ADCmean), were measured for up to three target lesions per patient. Rates of change between baseline and interim examinations (ΔSUVmax, ΔSUVmean, ΔADCmin, and ΔADCmean) were compared, using ANOVAs, between the four end-of-treatment (EOT, after six cycles of immunotherapy) outcomes: complete remission (CR), partial remission (PR), stable disease (SD), or progressive disease (PD). Results Fifteen patients with 25 lesions were included. Lesion-based post hoc tests showed significant differences between CR and PR for ΔSUVmax (P < 0.001), ΔSUVmean (P < 0.001), and ΔADCmin (P = 0.044), and between CR and SD for ΔSUVmax (P < 0.001), ΔSUVmean (P < 0.001), ΔADCmin (P = 0.021), and ΔADCmean (P = 0.022). No lesion showed PD at EOT. Conclusions Both quantitative interim 18F-FDG PET and interim DWI may possibly be useful to predict complete remission at end-of-treatment in MALT lymphoma patients after immunotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI